The SELECT trial (2023) demonstrated that Wegovy significantly reduces major adverse cardiovascular events (MACE) heart attack, stroke, cardiovascular death in patients with established cardiovascular disease and obesity
This will typically be the last measurement in this row, but may be located elsewhere on the label
Key Benefits of Tirzepatide Highest Efficacy of Any FDA-Approved Weight Loss Medication: The SURMOUNT-1 trial's 22.5% average weight reduction at the 15mg dose is the highest ever documented in a randomized controlled weight loss trial
Heart rate was measured at regular intervals throughout
Ongoing Support Enjoy monthly follow-ups with your doctor to ensure optimal results and minimize side effects
Other GI side effects, like nausea, diarrhea, and vomiting, were also more frequent but were usually mild to moderate